Clinical trials: Psilocybin, completed
Depressive Disorder, Depressive Disorder, Treatment-Resistant
Effect of Psilocybin on the Positive Valence System in Treatment-resistant Depression
The study hypothesis is that the antidepressant effect of psilocybin is mediated by a normalization of the functioning of the positive valence system.
- Conditions
- Depressive Disorder, Depressive Disorder, Treatment-Resistant, Hallucinogens, Reinforcement, Psychology
- Trial name
- PSILODAC (NCT06650800)
- Testing
- Psilocybin, MRI
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Depressive Symptoms, Anxiety
Psychopharmacology of Psilocybin in Cancer Patients
This research is being done to study the psychological effects of psilocybin in cancer patients. Psilocybin is a naturally occurring substance found in some mushrooms that some cultures have used for centuries in religious…
- Conditions
- Depressive Symptoms, Anxiety, Cancer
- Trial name
- NCT00465595
- Testing
- psilocybin
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Johns Hopkins University
Borderline Personality Disorder, Major Depressive Disorder
Psilocybin in Co-occuring Major Depressive Disorder and Borderline Personality Disorder
The primary objective of the study is to evaluate the safety and efficacy of psilocybin in adults with major depressive disorder (MDD) and borderline personality disorder (BPD).
- Trial name
- NCT05399498
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Chicago
Treatment Resistant Depression
Psilocybin in Depression Resistant to Standard Treatments
A single centre clinical trial to evaluate the feasibility, safety and efficacy of psilocybin, given under supportive conditions, in a randomised, blinded design in adult participants with treatment resistant major depressive…
- Trial name
- PsiDeR (NCT04959253)
- Testing
- Psilocybin assisted therapy
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- King's College London
Major Depressive Disorder
"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"
The purpose of this study is to examine the efficacy, safety, and tolerability of CYB003 compared to matching placebo as adjunctive treatment in participants with MDD.
- Trial name
- APPROACH (NCT06564818)
- Testing
- CYB003, Psychological Support
- Where
- 45 sites in United States
- Volunteers
- 223 people
- Sponsor
- Cybin IRL Limited
Depressive Disorder, Major
Psilocybin vs Escitalopram for Major Depressive Disorder: Comparative Mechanisms
This is a randomised double-blind clinical trial. The aim is to compare the efficacy and mechanisms of action of psilocybin, the primary psychoactive substance in 'magic mushrooms', with the selective serotonin reuptake inhibitor…
- Trial name
- Psilodep-RCT (NCT03429075)
- Testing
- Psilocybin + Escitalopram
- Where
- United Kingdom
- Volunteers
- 59 people
- Sponsor
- Imperial College London
Healthy
Acute Effects of 2C-B Compared With MDMA and Psilocybin in Healthy Subjects
4-bromo-2,5-dimethoxyphenethylamine (2C-B) is a psychoactive substance with reportedly similar acute effects to both the prototypical empathogen 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) and the classic psychedelic…
- Trial name
- 2C-B (NCT05523401)
- Testing
- 4-bromo-2,5-dimethoxyphenethylamine (10 mg), 4-bromo-2,5-dimethoxyphenethylamine (20 mg), 4-bromo-2,5-dimethoxyphenethylamine (30 mg)
- Where
- Switzerland
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Psilocybin
Precision Functional Brain Mapping in Psilocybin
This project will employ functional brain imaging to study the mechanism and immediate and long-term effects of psilocybin, a serotonin receptor 2A agonist, on cortical and cortico-subcortical brain networks in healthy adults.
- Trial name
- Psilocybin PFM (NCT04501653)
- Testing
- Psilocybin, Methylphenidate
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Alcohol-Related Disorders, Depressive Disorder
Psilocybin in Alcohol Use Disorder With Comorbid Depression
Up to 40% of people with alcohol use disorder (AUD) experience depression. Depression is a risk factor for early relapse of AUD after withdrawal in a controlled environment.
- Conditions
- Alcohol-Related Disorders, Depressive Disorder, Addiction
- Trial name
- PAD (NCT06235411)
- Testing
- Psilocybin therapy, Inactive Psilocybin therapy, Electroencephalogram
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Major Depressive Disorder
Psilocybin-assisted CBT for Depression
The primary objectives of this clinical investigation are to (1) determine the acceptability and feasibility of joining psilocybin-assisted therapy with cognitive-behavioral therapy (PA-CBT) for patients with depression, (2)…
- Trial name
- NCT05227612
- Testing
- Psilocybin, Cognitive behavioral therapy
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of California, Los Angeles
Treatment-resistant Depression
Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression
The study aims to investigate the safety and efficacy of oral psilocybin administered under supportive conditions in treatment-resistant major depression (TRD).
- Trial name
- EPIsoDE (NCT04670081)
- Testing
- Psilocybin, Nicotinamide
- Where
- 2 sites in Germany
- Volunteers
- 144 people
- Sponsor
- Central Institute of Mental Health, Mannheim
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Psilocybin Combined With Multidisciplinary Palliative Care in Demoralized Cancer Survivors With Chronic Pain
This phase I trial evaluates the side effects of psilocybin and how well it works under supportive care conditions in cancer survivors living with demoralization and chronic pain.
- Trial name
- NCT05506982
- Testing
- Psilocybin, Psychotherapy, Quality-of-Life Assessment
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Emory University
Healthy Volunteer
A Study Assessing Brain Activity, Safety, Tolerability, and Pharmacokinetics Following Multiple Doses of MLS101 (Psilocybin) in Healthy Volunteers
MLS101 is being developed as a low dose psilocybin, that can be administered to treat neurological and psychiatric conditions. The purpose of this trial is to investigate brain activity, safety, tolerability, and PK of multiple…
- Trial name
- NCT07050368
- Testing
- Psilocybin
- Where
- United Kingdom
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- MycoMedica Life Sciences PBC
Major Depressive Disorder
Microdosing Psychedelics to Improve Mood
This trial aims to examine the safety and efficacy of small (2mg) sub-hallucinogenic doses of psilocybin in people with Major Depressive Disorder.
- Trial name
- NCT05259943
- Testing
- Psilocybin first
- Where
- Canada
- Volunteers
- 39 people
- Sponsor
- Rotem Petranker
Distress, Depression
Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS Survivors
The purpose of this study is to determine whether psilocybin-assisted group psychotherapy is a safe and feasible treatment for demoralization in long-term AIDS survivors (LTAS).
- Conditions
- Distress, Depression, Grief
- Trial name
- NCT02950467
- Testing
- Psilocybin, Modified brief Supportive Expressive Group Therapy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Joshua Woolley
Treatment Resistant Depression
Long Term Follow Up Study to COMP 001 And COMP 003 Trials (P-TRD LTFU)
The primary objective of this study is to assess the long-term efficacy of psilocybin with respect to use of new antidepressant treatment, hospitalisations for depression, suicidality, and depressive severity rated using the…
- Trial name
- NCT04519957
- Where
- 8 sites in United States, Czechia and 3 more
- Volunteers
- 66 people
- Sponsor
- COMPASS Pathways
Psychogenic Nonepileptic Seizures, Psilocybin
Evaluation of the Effect of a Single Dose of Psilocybin on Neural Correlates of Cognitive Control in Patients With Psychogenic Nonepileptic Seizures
Psychogenic non-epileptic seizures (PNES) are functional paroxysmal motor disorders that may be clinically suggestive of epilepsy but are not associated with the electroencephysiological and electroencephalographic changes of…
- Trial name
- CRIPSY (NCT06647056)
- Testing
- Psilocybin, MRI
- Where
- France
- Volunteers
- 4 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Cocaine-Related Disorders
Psilocybin-facilitated Treatment for Cocaine Use
The primary purpose of this study is to evaluate the feasibility and estimate the efficacy of psilocybin-facilitated treatment for cocaine use.
- Trial name
- NCT02037126
- Testing
- Psilocybin, Diphenhydramine
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Alabama at Birmingham
Healthy
Acute Effects of MDMA Co-administration on the Response to Psilocybin in Healthy Subjects
The acute subjective effects of serotonin (5-HT)2A receptor stimulation with psilocybin in humans are mostly positive. However, negative effects such as anxiety, paranoid thinking, or loss of trust towards other people are common…
- Trial name
- MDMA-Psilo (NCT06884514)
- Testing
- Psilocybin, 3,4-Methylenedioxymethamphetamine
- Where
- Switzerland
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Alcohol Dependence
A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol Dependence
Several lines of evidence suggest that classic hallucinogens such as psilocybin can facilitate behavior change in addictions such as alcohol dependence.
- Trial name
- NCT02061293
- Testing
- Psilocybin, Diphenhydramine, Motivational Enhancement and Taking Action (META)
- Where
- 2 sites in United States
- Volunteers
- 95 people
- Sponsor
- NYU Langone Health